CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
10433 ETCTN Phase I/Ib trial evaluating the safety and efficacy of BET inhibitor, ZEN003694 with PD-1 inhibitor, nivolumab with or without CTLA-4 inhibitor, ipilimumab in solid tumors Adult CIRB - Early Phase Emphasis
10434 ETCTN Randomized Phase 2 Study of CPX-351 + Pomalidomide versus CPX-351 in Newly Diagnosed AML with MDS-Related Changes Adult CIRB - Early Phase Emphasis
10437 ETCTN A Single Arm Phase II Study of Bone-targeted Sn-117m-DTPA in Symptomatic Castration Resistant Prostate Cancer with Skeletal Metastases Adult CIRB - Early Phase Emphasis
10440 ETCTN A Phase 1/1a Study of Venetoclax, MLN9708 (ixazomib citrate) and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis Adult CIRB - Early Phase Emphasis
10445 ETCTN Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer Adult CIRB - Early Phase Emphasis
10449 ETCTN A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer Adult CIRB - Early Phase Emphasis
10450 ETCTN A Phase 1b Trial of M3814 (Peposertib) in Combination with Lutetium 177 Dotatate for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Adult CIRB - Early Phase Emphasis
10464 ETCTN A Phase 1 Study of Olaparib in Combination with Durvalumab (MEDI4736) and Concurrent Radiation Therapy Following First-Line Chemotherapy in Locally Advanced Unresectable Pancreatic Cancer Adult CIRB - Early Phase Emphasis
10466 ETCTN A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer Adult CIRB - Early Phase Emphasis
10476 ETCTN A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers Adult CIRB - Early Phase Emphasis